Evidence map›Paper›PMID 36043121›Full record

ArticleNeuro-oncology advances

Real-time PACS-integrated longitudinal brain metastasis tracking tool provides comprehensive assessment of treatment response to radiosurgery.

Gabriel Cassinelli Petersen, Khaled Bousabarah, Tej Verma, Marc von Reppert, Leon Jekel, Ayyuce Gordem, Benjamin Jang, Sara Merkaj, Sandra Abi Fadel, Randy Owens and 5 more

Open access · goldAbstract read
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 20 citations in OpenAlex.

  1. Observational
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Automatically tracking brain metastases after stereotactic radiosurgery.Physics and imaging in radiation oncology · 2023
    Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 2 countries.

Gabriel Cassinelli PetersenDepartment of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut, USA.ORCID https://orcid.org/0000-0002-4546-0567
Khaled BousabarahVisage Imaging GmbH, BerlinGermany.
Tej VermaNew York University, New York City, New York, USA.
Marc von ReppertDepartment of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut, USA.
Leon JekelDepartment of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut, USA.
Ayyuce GordemDepartment of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut, USA.
Benjamin JangDepartment of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut, USA.
Sara MerkajDepartment of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut, USA.
Sandra Abi FadelDepartment of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut, USA.
Randy OwensVisage Imaging Inc., San Diego, California, USA.
Antonio OmuroDepartment of Neurology, Yale School of Medicine, New Haven, Connecticut, USA.
Veronica ChiangDepartment of Neurosurgery, Yale School of Medicine, New Haven, Connecticut, USA.
Ichiro IkutaDepartment of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut, USA.
MingDe LinDepartment of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut, USA.
Mariam S AboianDepartment of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut, USA.
Yale University · USNew York University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Treatment of brain metastases can be tailored to individual lesions with treatments such as stereotactic radiosurgery. Accurate surveillance of lesions is a prerequisite but challenging in patients with multiple lesions and prior imaging studies, in a process that is laborious and time consuming. We aimed to longitudinally track several lesions using a PACS-integrated lesion tracking tool (LTT) to evaluate the efficiency of a PACS-integrated lesion tracking workflow, and characterize the prevalence of heterogenous response (HeR) to treatment after Gamma Knife (GK). Methods: We selected a group of brain metastases patients treated with GK at our institution. We used a PACS-integrated LTT to track the treatment response of each lesion after first GK intervention to maximally seven diagnostic follow-up scans. We evaluated the efficiency of this tool by comparing the number of clicks necessary to complete this task with and without the tool and examined the prevalence of HeR in treatment. Results: A cohort of eighty patients was selected and 494 lesions were measured and tracked longitudinally for a mean follow-up time of 374 days after first GK. Use of LTT significantly decreased number of necessary clicks. 81.7% of patients had HeR to treatment at the end of follow-up. The prevalence increased with increasing number of lesions. Conclusions: Lesions in a single patient often differ in their response to treatment, highlighting the importance of individual lesion size assessments for further treatment planning. PACS-integrated lesion tracking enables efficient lesion surveillance workflow and specific and objective result reports to treating clinicians.

Indexed as

brain metastasis trackingheterogenous responselesionradiosurgeryresponse to treatment

Identifiers

PMID36043121
PMCPMC9412827
OpenAlexW4288037168

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.